Smarter leaders trust GlobalData

Data Insights Cell & gene therapy in pharma: iPSCs

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Johnson & Johnson

F. Hoffmann-La Roche Ltd

View all

According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

iPSCs is a key innovation area in cell & gene therapy

Induced pluripotent stem cells (iPSCs) are a type of stem cell that can be generated directly from adult cells, such as skin cells or blood cells, by using defined factors such as transcription factors. These cells can differentiate into any type of cell in the body, making them a potentially powerful tool for regenerative medicine.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 210+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of iPSCs.

Key players in iPSCs – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to iPSCs

I'rom Group, formerly I'rom Holdings, is a diversified company that offers contract research, clinical trials and regenerative medicine services. The company operates through four business segments. The Site Management Organization (SMO) segment provides support services for contracting or conducting clinical trials. The Contract Research Organization (CRO) segment provides clinical trial operations for pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services.

Allele Biotechnology and Pharmaceuticals, and Johnson & Johnson are some of the other key patent filers in iPSCs.

In terms of application diversity, Megakaryon leads the pack, while Touchlight Genetics and Ono Pharmaceutical stood in the second and third positions, respectively.

By means of geographic reach, BioLamina held the top position, followed by F. Hoffmann-La Roche and Fujifilm.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.